IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
A fresh licensing deal tidies up years of work between the two companies.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
